Summus Raises $19.5 Million

To expand solutions solving the access problem in specialty care

Summus, the leading virtual health company focused in specialty care, announced today that it raised $19.5 million to support the company’s continued growth and work to solve the access problem to high quality physicians. Following a previous investment round in 2022, Summus has now raised $70 million to expand its innovative approach to care.

The company’s proprietary marketplace model empowers patients, families, caregivers and physicians to share and access high quality specialty expertise — across all health questions, at any point in the journey. By accelerating access to high quality physicians, Summus delivers best-in-class clinical guidance, advocacy and navigation. Summus works with leading employers, health plans, physician groups and leading medical institutions to provide a broad portfolio of solutions that improves access to quality care and improves outcomes.

“Durable, category defining companies naturally evolve and expand their aperture to serve more people over time. We are investing to meet the explosive demand for Summus solutions across the healthcare ecosystem,” said Mitchell Rales, Co-founder and Executive Chairman, Danaher Corporation.

In supporting more than 2 million lives, 98% of Summus members report that they better understand what to do in the next stage of their healthcare journey. Since 2020, consistent feedback from Summus members and physicians reflect universal recognition of the access and insights through Summus that would not otherwise have been available.

“The value of accessing high quality physicians in an expedient manner is vital — for peace of mind, optimizing treatment paths, and driving better outcomes. We continue our commitment to put high quality physicians, the most trusted party in healthcare, at the center of decisions big and small,” said Julian Flannery, Summus CEO and Co-founder.

The investment will focus on further scaling growth for the organization, including meeting demand for Summus’ innovative solution to support primary care physicians in a peer-to-peer environment, and enhancing condition-specific, personalized journeys for patients to access the best care with the most trusted physicians.

“We remain inspired by the Summus team and the value proposition they bring to the healthcare ecosystem. In providing access to thousands of the world’s most talented physicians to patients, families and physicians who need their expertise, we see Summus changing lives on a daily basis. We’re grateful to have the opportunity to continue to support Summus as they expand their capabilities to solve the critical issues of access to quality healthcare today,” said Rick Buhrman, Co-Founder and Co-CEO, Sator Grove Holdings. “I am impressed by the continued innovation, commitment and expertise of the Summus team, and am thrilled to see their growth and recognition in the market for bringing new solutions to physicians and patients around the world.”

SourceSummus

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version